SOLOMON MOSHEYEV: Open Payments
NPI 1144621590 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$578 in 23 payments from 9 companies in 2025. Trend: 2023 $217 · 2024 $311 · 2025 $578
Food & beverage: $578
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 4 | $129 |
| E.R. Squibb & Sons, L.L.C. | 5 | $109 |
| Luye Pharma (USA) Ltd. | 3 | $76 |
| Lundbeck LLC | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Alkermes, Inc. | 2 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
Products named: COBENFY, ERZOFRI EXTENDED-RELEASE, SPRAVATO, REXULTI, ARISTADA, INVEGA SUSTENNA, ABILIFY MAINTENA, CAPLYTA.
Industry payments across NY — which companies pay providers there.
